2022
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides). JAMA Dermatology 2022, 158: 1031-1039. PMID: 35857290, PMCID: PMC9301595, DOI: 10.1001/jamadermatol.2022.2749.Peer-Reviewed Original ResearchConceptsT-cell lymphomaAdverse eventsHypericin-photodynamic therapyIndex lesionClinical trialsEarly-stage cutaneous T-cell lymphomaMycosis fungoides cutaneous T-cell lymphomaActive drugCommon treatment-related adverse eventsDrug-related serious adverse eventsResponse rateTreatment-related adverse eventsPhotodynamic therapyCutaneous T-cell lymphomaEnd pointLong-term adverse effectsLesion response ratePlaque-type lesionsPrimary end pointSecondary end pointsSerious adverse eventsWeeks of therapySignificant clinical responseApplication site reactionsWeeks of treatment
2013
Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
Huang J, Cowper S, Moss J, Girardi M. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides. Journal Of Drugs In Dermatology 2013, 12: 487-9. PMID: 23652902.Peer-Reviewed Case Reports and Technical NotesConceptsExcimer laser therapyOral bexaroteneLaser therapyMycosis fungoides lesionsMinimal side effectsMF plaquesLocal erythemaMycosis fungoidesTreatment regimenCutaneous lesionsMF lesionsHistologic resolutionSide effectsTherapyBexaroteneLesionsUltraviolet ARegimenPUVAPatientsTreatmentPlaquesCase experienceFungoidesErythema
2003
Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow
Girardi M, Knobler R, Edelson R. Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. Hematology/Oncology Clinics Of North America 2003, 17: 1391-1403. PMID: 14710891, DOI: 10.1016/s0889-8588(03)00106-0.Peer-Reviewed Original ResearchConceptsLow side effect profileSide effect profilePotential novel strategyMechanism of actionImmunosuppressive medicationsExtracorporeal photochemotherapyEffect profileTransplant rejectionTreatment of cancerClinical recordsRole of ECPClinical studiesT cellsTreatment considerationsModern therapeuticsTreatmentNovel strategyGVHDMedicationsAutoimmunityCTCLMalignancyECPTherapyCancer